Now through the launch of the C2N PrecivityAD™ test, health care providers can prescribe a blood test that is precise, easy to administer, and can help detect if certain markers for Alzheimer’s disease, a neurological disease that can cause a decline in memory and thinking, are present in the brain.*Researchers have found the PrecivityAD™ test results to be an effective indicator of Alzheimer’s disease pathology among people with early memory changes.** The test is simple to administer, does not involve any radiation, and is non-invasive.

These features make it more accessible than other diagnostic methods that health care providers use to evaluate cognitive impairment.

Individuals with concerns about their memory or thinking abilities can now talk to their health care provider about a blood test that may help them understand their condition and what they can proactively do.

A breakthrough in Alzheimer’s disease has arrived with the C2N Diagnostics (C2N) PrecivityAD™ blood test.
Knowing that your symptoms are due to Alzheimer’s can help inform your doctor to prescribe specific Alzheimer’s treatments in order to aid in the management of the disease. If your symptoms are not due to Alzheimer’s (e.g. a normal test result), your health care provider can search for other causes, some of which can be treated with different interventions. You also may be eligible to enroll in clinical trials as a result of the PrecivityAD™ test results.

The PrecivityAD™ test is new and is not currently covered by private insurance payers, Medicare or Medicaid. Patients are responsible for paying out-of-pocket for the test. A financial assistance program is available for those patients that medically and financially qualify. In addition, a six-month, interest-free payment plan is also available to help pay for the test.

You and your health care provider can learn more at: www.PrecivityAD.com or by calling 1-877-C2N-DIAG (226-3424)

---

* The PrecivityAD™ APS scores are in a range of Low, Intermediate and High. Low APS: 0-36 (low likelihood of amyloid plaques); Intermediate APS: 37-57 (does not distinguish between presence or absence of amyloid plaques); High APS: 57-100 (high likelihood of amyloid plaques). Approximately 10-15% of patients who take the PrecivityAD™ test will receive a score within the intermediate range. For those patients, further diagnostic evaluation may be needed to address the underlying cause(s) of the patient’s cognitive symptoms.

** C2N data on file.